首页> 外文期刊>Cancer investigation >Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center.
【24h】

Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center.

机译:基于网络的乳腺癌预测算法在多学科肿瘤学中心辅助化疗决策中的实用性。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Adjuvant drug therapy can extend survival for breast cancer patients, but the balance between costs and benefits may be difficult to estimate. Software programs have been developed for this purpose and recently have become available online. Here, we describe our experience using a web-based program to support adjuvant decision making at a multidisciplinary breast cancer Tumor Board in a university-affiliated oncology center. PATIENTS AND METHODS: One hundred two adjuvant breast cancer cases were discussed by the Tumor Board over a four-month period, with a provisional treatment plan being formulated after each discussion. Program data predicting 10-year risks and benefits were shared with board members after each provisional plan and any change in recommendation was recorded. A user survey was conducted to assess the perceived strengths and weaknesses of the program. RESULTS: Treatment decisions were changed in 12.7 percent of cases (13/102) after consideration of data from the program. Most of these (76.9 percent) were node-negative ER-positive cases, with the most common reason for change being a lower-than-expected added survival benefit from less intensive chemotherapy regimens (ACx4 or CMF; 81.8 percent). In certain recurrent scenarios, the program was perceived to have limitations that led to retention of the original management plan despite data that might otherwise have favored different treatment. On completion of the study period, clinicians' attitudes to the program ranged from enthusiasm to caution. CONCLUSION: Although not replacing clinical judgement, these findings support the value of this web-based program as a decision making adjunct that can help clinicians to separate risk and benefit, compare the added value of different therapeutic interventions in a given clinical context, and present more balanced information about treatment options to patients.
机译:目的:辅助药物治疗可以延长乳腺癌患者的生存期,但成本和收益之间的平衡可能难以估计。为此目的已经开发了软件程序,并且最近可以在线使用它们。在这里,我们描述了一个基于网络的程序在一个大学附属肿瘤学中心的多学科乳腺癌肿瘤委员会中支持辅助决策的经验。患者与方法:肿瘤委员会在四个月的时间内讨论了102例辅助性乳腺癌病例,并在每次讨论后制定了临时治疗计划。在每个临时计划完成后,与董事会成员共享了预测十年风险和收益的计划数据,并记录了建议的任何变更。进行了用户调查,以评估该程序的优缺点。结果:在考虑了该计划的数据之后,在12.7%的病例中改变了治疗决策(13/102)。其中大多数(76.9%)是淋巴结阴性的ER阳性病例,最常见的改变原因是强度较低的化疗方案(ACx4或CMF; 81.8%)增加的生存获益低于预期。在某些经常发生的情况下,尽管数据可能会偏向于不同的处理方式,但该程序仍被认为具有局限性,导致保留了原始管理计划。在研究期结束后,临床医生对该计划的态度从热情到谨慎不等。结论:尽管不能取代临床判断,但这些发现支持该基于网络的计划的价值,可以作为决策辅助,帮助临床医生分离风险和收益,比较给定临床背景下不同治疗干预措施的附加价值,并提出有关患者治疗选择的更平衡的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号